A Case of Metastatic Breast Cancer with HER2 Gene Amplification that Responded Completely to Single Agent Trastuzumab
-
- Tsutani Yasuhiro
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center
-
- Ohsumi Shozo
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center
-
- Aogi Kenjiro
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center
-
- Taira Naruto
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center
-
- Kataoka Masaaki
- Radiology, National Hospital Organization Shikoku Cancer Center
-
- Hamamoto Yasushi
- Radiology, National Hospital Organization Shikoku Cancer Center
-
- Rieko Nishimura Rieko Nishimura
- Pathology, National Hospital Organization Shikoku Cancer Center
-
- Takashima Shigemitsu
- Departments of Surgery, National Hospital Organization Shikoku Cancer Center
この論文をさがす
抄録
An 80-year-old woman visited our hospital with a massive ulcerated tumor in the upper lateral quadrant of the right breast. Her performance status was 2. Histopathologically, a mass consisting of a huge primary tumor and metastatic axillary lymph nodes was seen and invasive ductal carcinoma was diagnosed. Both estrogen and progesterone receptors were negative. Herceptest® (DakoCytomation, Glostrup, Denmark) showed 2 + staining and HER2 amplification was detected by fluorescent in situ hybridization. CT revealed multiple lung metastases. Her old age and performance status of 2 made aggressive chemotherapy difficult. After receiving 5'-DFUR 600 mg/day as the first line treatment for two months, the tumors progressed. As second-line treatment, single agent therapy with a loading dose, a trastuzumab 4 mg/kg followed by 2 mg/kg weekly was recommended. The patient also received 60 Gy radiotherapy. Six months after the second line treatment, the breast tumor disappeared and only a scar remained on the chest wall and axilla. CT showed no lung tumors. During the trastuzumab treatment, no adverse effect was observed. Her performance status improved to zero, and she is alive and free from the disease 24 months after the disappearance of the tumor.
収録刊行物
-
- Breast Cancer
-
Breast Cancer 13 (4), 374-377, 2006
日本乳癌学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679456694400
-
- NII論文ID
- 130004467468
- 10019261664
-
- NII書誌ID
- AA1103354X
-
- ISSN
- 18804233
- 13406868
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可